Vibegron: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: February 20, 2026🚩 Report this page

Vibegron

Drugs For Urinary Frequency and Incontinence

Sold as Obgemsa

GB MHRAEU EMA

Drug class: Drugs For Urinary Frequency and Incontinence
Availability: See label
Markets covered: 2
Products on record: 2

G04BDDrugs For Urinary Frequency and Incontinence

Overview

Vibegron is an active pharmaceutical ingredient in the Drugs For Urinary Frequency and Incontinence group (G04BD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	February 20, 2026
EU European Union	EMA	1	July 8, 2025

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised February 20, 2026[1]

Obgemsa is indicated in symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.

How to take

EUEuropean Union· EMA

1 product

Uses

EUOfficial regulatory label· revised July 8, 2025[2]

Obgemsa is indicated in symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.

How to take

Drug interactions

Known interactions involving Vibegron. Select one for details. This list is informational and not a complete interaction checker.

Darifenacin Digoxin Fesoterodine Flavoxate Mirabegron Oxybutynin Solifenacin Tolterodine Trospium

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PLGB006030250 · revised February 20, 2026
[2]European Medicines Agency · EMEA/H/C/005957 · revised July 8, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised February 20, 2026[1]

0%). 9%. 2% each). Tabulated list of adverse reactions The table below reflects the adverse reactions observed with vibegron obtained from the phase 3 12-week study, phase 3 long-term extension study and post-marketing data. The frequency of adverse reactions is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000) and not known (cannot be established from the available data).
Table 1:
Adverse reactions reported for vibegron 75 mg System organ class Adverse reaction Frequency Infections and infestations Urinary tract infection Common Nervous system disorders Headache Common Vascular disorders Hot flush Uncommon Gastrointestinal disorders Constipation, Diarrhoea, Nausea Common Skin and subcutaneous tissue disorders Rasha Uncommon Renal and urinary disorders Urinary retentionb Uncommon Investigations Residual urine volume increased Common a includes rash pruritic and rash erythematous b includes urinary straining Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised February 20, 2026[1]

Patients with bladder outlet obstruction and patients taking antimuscarinics medicinal products for OAB Urinary retention has been reported in patients taking vibegron. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medicinal product concomitantly with vibegron treatment.
Signs and symptoms of urinary retention should be monitored before and during the treatment with vibegron, particularly in patients with clinically significant bladder outlet obstruction, in patients with conditions predisposing for bladder outlet obstruction, and in patients taking muscarinic antagonist medicinal product concomitantly with vibegron.
Vibegron should be discontinued in patients who develop urinary retention. Excipients Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

This is not medical advice. Consult a qualified healthcare professional.